Peter Lawson

Stock Analyst at Barclays

(1.21)
# 1603
Out of 5,325 analysts
131
Total ratings
33.70%
Success rate
-3.78%
Average return
41 Stocks
Name Action Price Target Current % Upside Ratings Updated
RCUS Arcus Biosciences
Maintains: Overweight
29 14
8.13 72.2% 7 Apr 23, 2025
IOVA Iovance Biotherapeut...
Maintains: Overweight
22 5
3.25 53.85% 6 Apr 14, 2025
BMEA Biomea Fusion
Maintains: Equal-Weight
11 3
2 50% 5 Apr 2, 2025
TCRX TScan Therapeutics
Maintains: Overweight
14 3
1.59 88.68% 2 Mar 7, 2025
GERN Geron
Maintains: Overweight
9 4
1.41 183.69% 1 Feb 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
25 29
37.04 -21.71% 5 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
48 32
9.11 251.26% 7 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
54 60
38.3 56.66% 3 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
14 17
3.13 443.13% 5 Sep 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
32 33
12.97 154.43% 4 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
5
n/a n/a 4 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
92 66
30.11 119.2% 2 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 8
1.67 379.04% 8 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
75 105
85.58 22.69% 10 Jul 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 31
11.82 162.27% 2 Jul 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
13 17
8.95 89.94% 3 Jun 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
18 13
1.5 766.67% 1 May 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Equal-Weight
9 26
25.59 1.6% 6 Apr 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
47 63
41.13 53.17% 3 Feb 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
6 10
1.36 635.29% 3 Feb 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
27 31
31.23 -0.74% 6 Dec 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
2 1
0.27 270.37% 2 Aug 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
7 5
0.89 461.8% 4 Aug 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
175 50
n/a n/a 2 Aug 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
210 120
6.33 1795.73% 2 Aug 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
30
8.83 239.75% 1 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
7 4
0.74 372.97% 4 Jul 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
355 365
76.17 379.19% 1 Aug 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
46
28.44 61.74% 2 Oct 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
40
n/a n/a 1 May 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
30
0.68 4311.76% 1 Mar 4, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
33
1.47 2144.9% 1 Mar 4, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Underweight
28
10.98 155.01% 1 Mar 4, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
65 75
n/a n/a 2 Dec 4, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
49
0.47 10325.53% 1 May 31, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
21
n/a n/a 1 Apr 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
19 5
n/a n/a 4 Apr 9, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
16 45
39.45 14.07% 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
17 45
1.59 2730.19% 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 3 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
70
0.79 8760.76% 1 Jul 14, 2017